Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...
Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...
Over the past few years, Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those ...
Abbott Laboratories closed $4.01 short of its 52-week high ($121.64), which the company reached on March 8th.
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...
3d
Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...
On Thursday, Piper Sandler initiated coverage on Abbott Laboratories (NYSE:NYSE:ABT) stock, assigning an Overweight rating and setting a price target of $131. The firm highlighted the company's ...
On Thursday, Piper Sandler initiated coverage on Abbott Laboratories (NYSE:NYSE:ABT) stock, assigning an Overweight rating and setting a price target of $131. The firm highlighted the company's strong ...
Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback